Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Red blood cell (RBC) transfusions should be restricted to those individuals with severe anemia in patients with heart disease, the American College of Physicians (ACP) recommends in a new clinical practice guideline published in Annals of Internal Medicine, ACP's flagship journal.
ACP also recommends against using erythropoiesis-stimulating agents (ESAs) in patients with mild to moderate anemia and congestive heart failure (CHF) or coronary artery disease (CHD) because the harms, including increased risks of thromboembolic events and stroke rates, outweigh the benefits.
"Transfusion may benefit patients with lower hemoglobin levels, less than 7 - 8 g/dL, but the evidence suggests that red blood cell transfusion for milder anemia in patients with heart disease does not improve mortality," said Molly Cooke, MD, FACP, president, ACP.
"The evidence evaluating the impact of ESAs in patients with heart disease did not show improved health outcomes."
ACP's guideline also includes advice to help physicians practice high value care.
Anemia is common in patients with heart disease. Anemia is present in approximately one-third of patients with CHF and 10 to 20 percent of patients with CHD. Anemia can worsen cardiac function and is associated with poor outcomes, including increased risk of hospitalization, decreased exercise capacity, and poor quality of life. It is unclear whether anemia directly and independently leads to these poor outcomes or whether it reflects a more severe underlying illness.
Because of the poor outcomes associated with anemia in patients with heart disease, a number of treatments have been tried, including RBC transfusions, ESAs, and iron replacement. Overall, it is unclear whether these strategies improve outcomes.
Emerging evidence shows short term benefit of one form of intravenous iron in patients with CHF and low ferritin (less than 100), but ACP found evidence lacking on long-term outcomes. Additionally, the effect of oral iron and how it compares to intravenous iron for treating anemic patients with heart disease is unknown.
To develop the guideline, ACP looked at the evidence to answer three questions related to the treatment of anemia in patients with CHF or CHD:
Annals of Internal Medicine also published a summary for patients.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Blood / Hematology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
American College of Physicians. "Tighter transfusion strategy recommended to treat anemia in patients with heart disease." Medical News Today. MediLexicon, Intl., 3 Dec. 2013. Web.
18 Apr. 2014. <http://www.medicalnewstoday.com/releases/269584>
American College of Physicians. (2013, December 3). "Tighter transfusion strategy recommended to treat anemia in patients with heart disease." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/269584.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.